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Abstract
Introduction: The non-ST elevation-acute coronary syndrome (NSTE-ACS) accounts for more than 
50% of the total number of patients with ACS. The mortality rates after non-ST-elevation myocardial 
infarction (MI) are not significantly different when compared with patients with ST-segment elevation 
MI. The aim of the present study was to investigate whether the assessment of clinical, laboratory, and 
instrumental data during hospital stay provides any additional independent information in predicting 
the 3-year major cardiac events after NSTE-ACS. Patients and Methods: We observed 490 consecutive 
patients, who were admitted to the emergency cardiology department with NSTE-ACS. The patients’ 
baseline characteristics, blood analysis, left ventricle (LV), and renal function data were assessed 
and analyzed. The median followup time was 36 months. The endpoint was cardiovascular death. 
Results: The results of our study show that the risk of cardiovascular death during the 3 years’ follow-
up after multivariate adjustment increases with older age (>64 years), history of diabetes, prior MI 
and history of angina pectoris, lower ejection fraction (<50%), degree of myocardial hypertrophy (the 
thickness of the interventricular septum >1.25 mm) of the LV and the degree of diastolic dysfunction 
(E-wave deceleration time <150 ms), silent myocardial ischemia during first 24-h, high pulse pressure 
on day 1 (>49 mm Hg), glucose level >7.5 mmol/l on admission, and moderate kidney dysfunction 
(creatinine level and its clearance <60 ml/min). Conclusion: In patients with NSTE-ACS, we report 
the cardiovascular death risk factors within the 3-year follow-up period in the present study. We, 
thus, conclude that it is important to identify the patients with high risk of future cardiovascular 
complications.
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Introduction
Coronary artery disease remains one of 
the leading causes of death worldwide. 
Approximately 1 million new and recurrent 
acute myocardial infarctions (AMI) occur 
annually in the United States.[1] Each year in 
Ukraine, more than 50,000 patients experience 
an acute coronary event[2] and more than 50% 
of them have a non-ST elevation acute coronary 
syndrome (NSTE-ACS) with increasing of the 
proportion of NSTE-ACS events per year.[3]
Mortality rates after AMI have decreased over 
the past decades but differ between ST-segment 
elevation MI (STEMI) and non-STEMI (NSTEMI) 
patients.[4] Data from randomized trials have 
shown that hospitalized patients with NSTEMI 
have a lower risk of death during the 1st few 
weeks after MI whereas are at the higher risk 
for cardiovascular outcomes over the long-term 
follow-up than those with STEMI.[5,6]
Patients with ACS should undergo risk 
stratification to predict those who are at high 
risk for short- and long-term adverse outcomes. 
Among patients with NSTE-ACS, which 
includes NSTEMI and unstable angina (UA), 
risk stratification begins soon after admission 
to detect patients at high risk during the early 
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hospital phase. Subsequent risk stratification is aimed to 
predict patients being at increased risk after discharge.[7]
The aim of the present study was to investigate whether the 
assessment of clinical, laboratory, and instrumental data during 
hospital stay provides additional independent information in 
predicting 3-year major cardiac events after NSTE-ACS.
Patients and Methods
Study population
In an observational, retrospective cohort study, a total of 490 
consecutive patients admitted to the emergency cardiology 
department with a diagnosis of NSTE-ACS were included. 
The definition of NSTE-ACS was based on the following 
criteria: (a) Prolonged (>20 min) anginal pain at rest; (b) and 
electrocardiographic (ECG) findings suggestive of ischemia: 
ST segment depression (>1 mm) or inversion of the T wave 
(>1 mm); and/or (c) positive biomarkers of necrosis (troponins 
or MB fraction of creatine kinase).
Inclusion criteria
The following criteria were included in the study:
1. Patients with NSTE-ACS <24 h from the last pain at rest.
2. Changes on the ECG:
 • ST depression >1 mm
 • Transient ST elevations >1 mm
 • Inversion of the T wave >2 mm
 •  Absence of new changes on the ECG in case of history 
of MI.
3. <72 h from the time of destabilization.
Exclusion criteria
The following criteria were excluded from the study:
1. Valvular heart diseases
2. Chronic heart failure NYHA III-IV
3. Cardiogenic shock
4. Severe liver dysfunction (AST or ALT > 3 × ULN)
5. Kidney dysfunction (creatinine level and its clearance 
[CrCl] <30 ml/min)
6. Severe infection
7. Malignant tumor or active cancer.
Study protocol
Each patient underwent a physical examination with 
measuring of blood pressure (BP), heart rate, body mass index, 
and followed by standard diagnostic tests (ECG, biomarkers). 
Furthermore, we analyzed complications during in-hospital 
period and laboratory data (C-reactive protein, fibrinogen, 
erythrocyte sedimentation rate [ESR], white blood cells [WBC], 
and creatinine) on the day 1 and on the day 10. Two-dimensional 
echocardiography was performed on the day 1 after admission 
to the hospital and Holter ECG monitoring and heart rate 
variability (HRV) on the days 1, 3, 7, and 10 of in-hospital stay. 
Renal function was estimated using CrCl on admission and 
on the day 10 using the Cockcroft–Gault formula. Treatment 
of all patients was according to the National and European 
recommendations and standards.[7]
This study was approved by the Ethics Committee at the 
National Scientific Center, the M. D. Strazhesko Institute of 
Cardiology.
Endpoints
The endpoint was a composite of cardiovascular death, non-fatal 
MI, UA, and percutaneous coronary intervention with coronary 
artery stenting and coronary artery bypass grafting. Information 
regarding adverse events was obtained from patients or family 
doctors or patients’ relatives during phone calls.
Statistical analysis
Statistical analysis was assessed with “SPSS 13.0” software 
using Student’s t-test and χ2-test. Data were reported as means 
with standard deviation, and the categorical variables were 
expressed as numbers with percentages. A multivariate Cox 
regression analysis was performed for the confounding effects, 
and odds ratios and 95% confidence intervals were calculated. 
A value of P < 0.05 was considered statistically significant.
Results
Patients’ characteristics
All prognostic analyses in the present study were carried out using 
data from 490 patients. The baseline characteristics of the patients 
and medications are summarized in Tables 1 and 2 respectively.
Endpoint events
The median follow-up time was 36 months (interquartile range: 
32–39 months). The endpoint was monitored every 6 months, 
and the data of 94.90% of patients (n = 465) were available 
for analyses. Patients, who died during in-hospital stay and 
those without contact during follow-up, were excluded from 
analyses. Endpoint events during 3-year follow-up are 
presented in Table 3.
Results of our study show that the risk of cardiovascular death 
during 3-year follow-up after multivariate adjustment increases 
with older age (>64 years), history of diabetes, prior MI, and 
history of angina pectoris [Figure 1].
Lower ejection fraction (EF) (<50%), degree of myocardial 
hypertrophy (the thickness of the interventricular septum 
>1.25 mm) of the left ventricle (LV), and the degree of 
diastolic dysfunction (E-wave deceleration time [DT] <150 ms) 
were identified as independent predictors of cardiovascular 
mortality also [Figure 2].
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We hypothesized that depressed HRV could have a negative 
impact on cardiovascular death by suppressing parasympathetic 
and augmenting sympathetic components of HRV. High-
frequency (PH <18.5) and low-frequency (PL >81) components 
of HRV and total power (PT >15) were determined by spectral 
analysis [Figure 3].
Silent myocardial ischemia (SMI) - objectively documented 
ischemia in the absence of chest discomfort or an another 
anginal equivalent - is a major risk factor of poor prognosis.[8] 
We studied SMI during days 1, 3, 7, and 10 by 24 h Holter ECG 
monitoring, and only SMI during the first 24 h had a negative 
predictive impact.
Table 1: Study baseline characteristics
Number n=490
Clinical observation
Age, years 58,78 ± 0.44
Male 365 (74.49%)
Hypertension 379 (77.35%)
Coronary artery disease 355 (72.04%)
DM 79 (16.12%)
Current smoker 167 (34.08%)
History of chronic heart failure 51 (10.41%)
History of MI 194 (39.59%)
ВМІ >30 kg/m2 81 (16.53%)
ECG
Depression of ST segment 208 (42.45%)
Inverted T wave 277 (56.53%)
Transient ST-segment elevation 42 (8.57%)
DM: Diabetes mellitus, MI: Myocardial infarction, BMI: Body mass index, 
ECG: Electrocardiographic
Table 3: Endpoint events during 3-year follow-up
Endpoint events n=465
Cardiovascular death 58 (12.47%)
Non-fatal MI 38 (8.17%)
UA 81 (17.42%)
PTCA with stenting 56 (12.04%)
CABG 55 (11.83%)
UA: Unstable angina, MI: Myocardial infarction
Table 2: Treatment baseline characteristics
Medications n=490
Antiplatelet 490 (100%)
ASA 437 (89.18%)
Thienopyridines 143 (29.18%)
LMW heparins 357 (72.86%)
Standard heparin 78 (15.92%)
Beta-blockers 404 (82.45%)
ACE inhibitors 347 (70.82%)
Nitrates (oral) 337 (68.78%)
Nitrates (i.v.) 311 (63.47%)
Lipid-lowering 
therapies
203 (48.78%)
Figure 1: Impact of age, history of myocardial infarction, 
diabetes mellitus, and angina pectoris on cardiovascular 
death
Figure 2: Impact of left ventricle ejection fraction, myocardial 
hypertrophy, and diastolic dysfunction on cardiovascular 
death
Figure 3: Impact of heart rate variability on cardiovascular 
death
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Clinical history of arterial hypertension in MI is well 
known as a negative prognostic factor.[9] In our study, we 
established that low mean and high pulse pressure on the 
day 1 were significantly associated with cardiovascular 
mortality [Figure 4].
The high ESR levels on admission are found to be related to 
poor short- and long-term survival. Therefore, ESR evaluation 
on admission may be helpful to identify patients with a poor 
prognosis. In our study value, ESR >13 mm/h on admission was 
a cutoff point according to the Cox regression analyses.
Patients either with or without a prior history of diabetes 
mellitus (DM) may present with hyperglycemia during ACS, 
and hyperglycemia on admission remains an independent 
predictor of post-discharge mortality. Our data confirmed that 
glucose level >7.5 mmol/l on admission could be a negative risk 
factor for those patients without a history of DM.
Renal function should be measured in all patients with NSTE-
ACS during 1st h because it is important for dose adjustment 
of drugs and contrast agents released through the kidneys. On 
the other hand, estimated glomerular filtration rate (GFR) has a 
powerful relationship between the severity of renal dysfunction 
and poor outcomes. In our study, survival analysis showed that 
patients with moderate dysfunction (CrCl <60 ml/min) had a 
higher rate of cardiovascular death than patients with CfCl 
>60 ml/min [Figure 5].
Discussion
Optimal, evidence-based treatment after NSTE-ACS can only 
reduce the risk of an event. Even optimally treated patients face 
a residual risk of adverse cardiovascular outcomes due to the 
underlying disease process and a number of comorbidities.[10] 
Therefore, all post-NSTE-ACS patients should receive beta-
blockers and statins in recommended doses permanently, if 
not contraindicated.[11] Patients also require medications to 
modify risk factors, such as antihypertensive medications to 
achieve target BP, angiotensin-converting enzyme inhibitors 
for left ventricular dysfunction, and antihyperglycemic agents 
to maintain a goal of glucose level.[12]
In our study, we investigated the risk factors for the stratification 
of long-term outcomes. It is very important to identified 
patients with a high risk of future cardiovascular complications 
after discharge. The results of this study showed that older age, 
history of MI, previously diagnosed angina pectoris, diabetes, 
systolic dysfunction, HRV abnormality, elevated mean pulse BP 
and blood glucose findings at the time of hospital admission, 
and lower CrCl findings were the main factors significantly 
associated with an adverse long-term prognosis following 
hospital discharge for patients with NSTE-ACS after multivariate 
adjustment for the demographic characteristics, comorbidities, 
and hospital complications.
Older age and the presence of comorbidities have been 
recognized as critical factors in predicting the clinical outcomes 
in patients with ACS. In the present study, it was proved that 
existing coronary heart disease, DM, and renal disease were the 
main comorbidities led to a higher incidence of mortality. In an 
another large study, it was found that independent predictors 
of early mortality in NSTE-ACS patients included old age above 
60-year-old, Killip class, female gender, LV dysfunction, and 
renal failure.[12] In another such study, it was confirmed that DM, 
in addition to age and systolic LV dysfunction, was found to be 
independent predictors of early mortality in those patients.[13]
There are studies that suggest that hemodynamic measures can 
predict mortality, whereas the evidence of the prognostic value 
of hemodynamic measures in NSTE-ACS patients is limited. 
This research demonstrated the influence of LV hypertrophy 
and the degree of diastolic dysfunction on CV death, and our 
data coincide with the results of other authors.[14]
LVEF is a valid indicator of myocardial function and has shown 
by multiple studies to be an established predictor of adverse 
Figure 4: Impact of silent myocardial ischemia and mean 
pulse blood pressure on cardiovascular death
Figure 5: Impact of erythrocyte sedimentation rate, serum 
glucose, and glomerular filtration rate on cardiovascular 
death
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clinical outcomes. Data of a prospective cohort study showed 
that LVEF ≤50% was associated with high rates of adverse 
events, including death.[15]
Low HRV is usually considered as a negative long-term 
prognostic factor after an ACS. In our group of patients with 
a recent ACS, abnormal autonomic parameters have been 
correlated with long-term outcomes. These results support 
the significant prognostic value of traditional HRV parameters, 
and HRV measured close to the ACS onset may assist in risk 
stratification.[16]
According to the recent publications, the long-term mortality 
for patients with NSTE-ACS has been related to the extent 
of their comorbid disease burden.[17] In the present study, 
patients with NSTE-ACS were more likely to have several 
previous comorbid diseases, especially patients to have 
decreased survival if they had a history of angina pectoris, prior 
MI, and diabetes. Similarly, we found that systolic dysfunction 
and heart rate abnormalities were associated with decreased 
survival after hospital discharge.
If established risk assessment methods are not used, it leads to 
underestimate risk in high-risk patients and overestimate risk 
in low-risk patients.[18] In addition, physicians tend to estimate 
the risk based on the intensity of treatment received during 
the ACS. In particular, physicians underestimate risk associated 
with age and may consider younger ACS patients as having a 
more aggressive disease phenotype than older patients, while 
underestimating the impact of age-associated accumulated 
coronary artery damage.[19] Therefore, it is important that 
physicians should use validated objective measures of risk 
when assessing ACS patients.
Limitations
Our study has several limitations that should be considered 
when interpreting the present results. This was a single-center 
and observational uncontrolled study. The samples were 
restricted to patients discharged from our hospital with a 
successful follow-up, which may have resulted in selection 
biases and conclusions with limited generalizability. There was 
a tendency for cardiologists to perform conservative treatment 
for high-risk patients, which might have affected the final 
results. Finally, this study cannot exclude possible residual 
confounding by other measured and/or unmeasured factors 
including the treatment decisions of patients when NSTE-ACS 
occurred, which is an important source of prognosis.
There are currently limited data to guide clinical decision-
making around optimal secondary preventive therapies in NSTE-
ACS patients who survive after hospital discharge. On-going risk 
assessment is important in all post-MI patients, and clinicians 
should use the objective measures of evaluation whenever it 
possible, to avoid over- or under-estimating future risk.
Conclusion
Our findings suggested that, in patients with NSTE-ACS, the 
cardiovascular death risk factors for the 3-year follow-up were 
as follows:
• Demographic and clinical factors: Age, history of MI, 
history of angina pectoris, and DM.
• Instrumental: LV EF, LV hypertrophy, low DT, depressed 
HRV, and silent ischemia according to the results of Holter 
ECG monitoring and median pulse BP.
• Laboratory: ESR, glucose level, and GFR.
Future research efforts should focus on the study risk factors in 
patients after NSTE-ACS and evaluate the impact on long-term 
outcomes.
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